Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BEM-041
- Development stage
- Preclinical
- Lead developer
- Shanghai Benemae Pharmaceutical
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
**BEM-041** is a preclinical antidiabetic combination product from Shanghai Benemae Pharma that combines beinaglutide, a glucagon-like peptide 1 receptor agonist, with mealtime insulin. The program is intended to improve glycemic control in type 2 diabetes by integrating incretin-mediated glucose-dependent insulinotropic activity with prandial insulin replacement. ([benemae.com](https://www.benemae.com/product/research.html))
- Other names
- 贝那鲁肽 + 餐时胰岛素
02
Targets
Beyond the preview
Go deeper on BEM-041.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BEM-041.